Tofacitinib Inhibits Leukocyte Trafficking Across the Intestinal Endothelial Barrier in a Specific Cohort of Ulcerative Colitis Patients.
Sign Up to like & getrecommendations! Published in 2022 at "Inflammatory bowel diseases"
DOI: 10.1093/ibd/izab349
Abstract: The JAK/STAT inhibitor tofacitinib, recently approved for the treatment of ulcerative colitis, is found to modulate the intestinal endothelial barrier functions in directing the leukocyte adhesion and transmigration in ulcerative colitis patients displaying high levels… read more here.
Keywords: intestinal endothelial; endothelial barrier; colitis patients; colitis ... See more keywords